257928-43-1 Usage
General Description
"(R)-4-(4-(benzyloxy)phenyl)-1-(1-phenylethyl)-1,2,3,6-tetrahydropyridine" is a full label for a specific class of organic compounds that belong to the category of alkaloids and derivatives. It contains a tetrahydropyridine ring system (four hydrogen atoms attached to a six-membered nitrogenous ring), which has potential biological activity. This chemical compound is mainly characterized by the presence of two phenyl groups and a benzyloxy group attached to the ring system. Also, the "(R)" in the name signifies the relative configuration of the attached groups, implying that it is one of two possible stereoisomers. Although the specific uses or reactions involving this chemical are not stated, these types of complex organic molecules are commonly found in pharmaceuticals, materials science, and organic chemistry research.
Check Digit Verification of cas no
The CAS Registry Mumber 257928-43-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,7,9,2 and 8 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 257928-43:
(8*2)+(7*5)+(6*7)+(5*9)+(4*2)+(3*8)+(2*4)+(1*3)=181
181 % 10 = 1
So 257928-43-1 is a valid CAS Registry Number.
257928-43-1Relevant articles and documents
Process and intermediates for preparation of substituted piperidine-epoxides
-
, (2008/06/13)
The present invention concerns intermediates useful in and a process for the preparation of a compound of formula 1 or a salt thereof comprisingepoxidation of a compound of formula 2 or a salt thereof wherein A, R1and R2are as herein
Piperidine renin inhibitors: from leads to drug candidates
Maerki, H. P.,Binggeli, A.,Bittner, B.,Bohner-Lang, V.,Breu, V.,Bur, D.,Coassolo, Ph.,Clozel, J. P.,D'Arcy, A.,Doebeli, H.,Fischli, W.,et al.
, p. 21 - 28 (2007/10/03)
Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compounds potentially free of the drawbacks seen with peptidomimetic compounds so far. Synthetic optimization in two structural series focusing on improvement